文献速递肾小球疾病

肾脏疾病的补体抑制剂

Complement inhibitors for kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本文综述了补体在肾小球疾病及其他肾脏疾病发病中的作用,回顾了从早期针对C5的小规模研究到近期针对C3的大型多中心随机试验的证据,并探讨了补体靶向治疗的未来方向。

要点

  • 补体经典、凝集素和旁路三条途径的激活在罕见和常见肾小球病变中均起重要作用。
  • 补体抑制治疗证据从早期C5靶向小规模研究扩展至近期C3层面大型多中心随机试验。
  • 综述基于现有研究展望补体靶向治疗领域的未来方向。

核心结论

  • 补体激活通过经典、凝集素和旁路三条途径在罕见(如C3肾小球病)和常见(如免疫球蛋白A肾病)肾小球病变中起重要作用,为精准靶向治疗提供了途径。

研究设计与样本

  • 综述类文章,检索范围涵盖从早期针对C5的小规模研究到近期针对C3的大型多中心随机试验的补体抑制证据。

主要发现

  • 过去二十年对补体在肾小球疾病发病中作用的认识不断细化,并伴随着新型补体靶向治疗的发展。
  • 补体抑制研究已从早期聚焦C5靶向药物的小规模研究,发展到近期在补体通路更上游C3水平进行阻断的大型多中心随机试验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A refined understanding of the role of complement in the pathogenesis of glomerular and other kidney diseases has, over the past two decades, been matched by the development of novel, complement-targeting therapies. As we increasingly recognize the important role that complement activation across all three pathways-classical, lectin and alternative-plays in glomerular lesions both rare (e.g. C3 glomerulopathy) and common (e.g. immunoglobulin A nephropathy), we can identify avenues for precise, targeted approaches to modifying the natural history of these kidney diseases. In this review, we survey the evidence on using complement inhibition from the earliest, small-scale studies focusing on C5-targeting agents to more recent, large, multicenter, randomized trials utilizing complement blockade higher up in the complement pathway at the level of C3. We conclude by examining where the field of complement targeting therapy may be headed in light of these studies.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wooden B, Tarragon B, Navarro-Torres M, et al. Complement inhibitors for kidney disease. Nephrol Dial Transplant. 2023. PMID: 37218685. doi:10.1093/ndt/gfad079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。